Venus Remedies Gets Marketing Approval for Oncology Drugs in Israel and Colombia

Building on its international presence in the oncology space, Venus Remedies, a global leader in pharmaceutical innovation, has secured marketing authorisation for docetaxel from Israel and cytarabine from Colombia.

While docetaxel, an antineoplastic agent, is beneficial in the treatment of breast, prostate, head, neck and non-small cell lung cancer, cytarabine is useful in acute non-lymphocytic leukaemia, acute
lymphocytic leukaemia and chronic myelocytic leukaemia.

Israel's pharmaceutical market, valued at about $5 billion, is projected to grow at a five-year compound annual growth rate (CAGR) of 4.2% up to 2026. Israel has a dynamic pharmaceutical
expanse known for its innovation and commitment to healthcare excellence. The marketing authorisation for cytarabine from Colombia, on the other hand, marks a significant expansion of
Venus Remedies in the Latin American market. Colombia, the third-largest pharmaceutical market in South America projected to grow at a five-year CAGR of 3.1% up to 2026, has emerged as a vital player in the pharmaceutical industry, exhibiting robust growth and fostering innovation. The Colombian market dominated by oncology drugs has witnessed steady expansion.

Saransh Chaudhary, CEO, Venus Medicine Research Centre (VMRC), said these dual milestones reflect VMRC’s unwavering dedication to research and development. “Our team's
relentless pursuit of excellence in pharmaceutical innovation is evident in the approvals for docetaxel and cytarabine. We are excited about the prospect of bringing these advanced therapies to patients in Israel and Colombia, and we remain committed to exploring new frontiers in healthcare that align with our vision of a healthier world,” he said.

Hailing the achievement, Aditi K. Chaudhary, President, International Business, Venus Remedies, said, "These marketing approvals mark a significant stride in our global mission to enhance healthcare accessibility. One of the largest exporters of docetaxel, Venus Remedies is proud to include Israel in the list of countries it supplies docetaxel to, including Malaysia, Namibia, Myanmar, Panama,
Indonesia, Iraq, Tanzania, Germany, and Zimbabwe. Likewise, the market reach of Venus Remedies for cytarabine extends to Guinea-Bissau, Jordan, Namibia, Oman, Saudi Arabia, Tunisia and Venezuela, besides Colombia."